Nor ATG nor the IgG control affected the looked into cytokines in monocytes, whilst LPS strongly induced their particular expression (Figure S4). == 2 . several. actively suppressed the To cell proliferation induced by mature DC. These data suggest that besides its popular effect on To cells, ATG modulates the phenotype of DC in a tolerogenic way, which might Roflumilast N-oxide constitute an essential part of its immunosuppressive action in vivo. Keywords: allogeneic hematopoietic stem cell transplantation; dendritic cell; antithymocyte globulin; Grafalon; tolerogenic; indoleamine 2, 3-dioxygenase; immunosuppressive == 1 . Launch == Allogeneic hematopoietic stem cell transplantation (aHSCT) is one of the most effective remedies for hematologic malignancies. However , Roflumilast N-oxide graft-versus-host disease (GvHD) is still the major reason for mortality Roflumilast N-oxide in aHSCT [1]. Dendritic cells (DC) play a crucial role in the pathogenesis of GvHD. Yet aside from their particular ability to stimulate GvHD, DC can also show tolerogenic properties that may be exploited in the avoidance and treatment of GvHD [1]. Tolerogenic DC are characterized by a semi-mature phenotype with large expression of MHC II (major histocompatibility complex) and low manifestation of costimulatory B7 molecules. They primarily secrete immunosuppressive mediators, such as IL-10, and lack the production of proinflammatory cytokines such as IL-12 [2]. Immunosuppressive medication of patients undergoing aHSCT contains antithymocyte globulin (ATG)-Fresenius (now Grafalon), FANCD a polyclonal antibody-mixture raised in rabbits against the human lymphoblastic T cell line Jurkat [3]. Administration of ATG contributes to the depletion of To lymphocytes [4]. ATG also affects other defense cells, including dendritic cells (DC) [4], as it directly binds to different DC surface antigens such as CD1a, CD80, CD86, CD206, and HLA-DR [5, 6]. Furthermore, ATG induces diverse signaling pathways in DC, e. g., the activation of the proteins kinases ERK1/2 and p38, as well as Roflumilast N-oxide NF-B signaling [6], and depletes circulating DC [7]. However , since host-derived tissue-resident DC subsets persist over a extented period after aHSCT [8], the effects of ATG on DC most likely exceed depletion. And indeed, ATG interferes with various aspects of DC function: it modulates DC differentiation, inhibits maturation induced by diverse stimuli, suppresses the IL-12 secretion of mature DC, and reduces the ability of mature DC to activate T cells. Furthermore, it seems to stimulate a tolerogenic phenotype accompanied by mRNA manifestation of indoleamine 2, 3-dioxygenase (IDO) [5, 6, 9, 10]. In individuals with ATG prophylaxis, we previously reported systemic release of tryptophan metabolites on the day of aHSCT also indicating activation of IDO by ATG [11]. GUILLADO catalyzes the initial step of the tryptophan metabolism [12]. Its expression is actually a characteristic of tolerogenic DC and is associated with enhanced tryptophan degradation [13]. Both the deprivation of tryptophan and the accumulation of tryptophan metabolites represent potent immune-regulatory mechanisms [14, 15]. Additionally , IDO-expressing DC are able to stimulate regulatory To cells [14] and lead to renal allograft tolerance in mice [16]. Since published studies on the effect of ATG on human DC were conducted with different ATG preparations and experimental settings [5, 6, 9, 10], we chose ATG-Fresenius, which is authorized for GvHD prophylaxis and had the most powerful effect on the release of tryptophan metabolites in patients [11], and studied the effect of ATG on immature DC in the absence of any maturation stimulation. This environment reflects the clinical scenario where individuals receive ATG prior to aHSCT and tissue-resident immature DC encounter ATG. ATG induced a tolerogenic DC phenotype with increased manifestation of GUILLADO and a greater tryptophan metabolism. In accordance with their particular tolerogenic phenotype, ATG-DC negatively influenced the T cell proliferation induced by LPS-matured DC. These results clearly demonstrate that ATG is actually a potent tolerogenic stimulus to get DC. Additionally they suggest that the mechanism fundamental the medical effects of ATG on graft rejection and GvHD may go Roflumilast N-oxide considerably beyond To lymphocyte depletion. == 2 . Results == == 2 . 1 . ATG Induces a Semi-Mature Phenotype in DC == To investigate the influence of ATG on the maturation of DC, we cultivated monocyte-derived DC with or without LPS (10 ng/mL) or with a therapeutically relevant concentration of ATG-Fresenius (100 g/mL) (now Grafalon) [3]. In addition , we incubated DC with Alemtuzumab (100 g/mL), an additional immunosuppressive drug directed against lymphocytes that is approved to get the prevention of GvHD [17]. After forty eight h we analyzed the expression of CD1a,.